L M Ingebriktsen1, K Finne1, L A Akslen1,2, E Wik3,4. 1. Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway. 2. Department of Pathology, Haukeland University Hospital, Bergen, Norway. 3. Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway. Elisabeth.wik@uib.no. 4. Department of Pathology, Haukeland University Hospital, Bergen, Norway. Elisabeth.wik@uib.no.
Abstract
BACKGROUND AND OBJECTIVE: Breast cancer (BC) diagnosed at ages <40 years presents with more aggressive tumour phenotypes and poorer clinical outcome compared to older BC patients. Here, we explored transcriptional BC alterations to gain a better understanding of age-related tumour biology, also subtype-stratified. METHODS: We studied publicly available global BC mRNA expression (n = 3999) and proteomics data (n = 113), exploring differentially expressed genes, enriched gene sets, and gene networks in the young compared to older patients. RESULTS: We identified transcriptional patterns reflecting increased proliferation and oncogenic signalling in BC of the young, also in subtype-stratified analyses. Six up-regulated hub genes built a novel age-related score, significantly associated with aggressive clinicopathologic features. A high 6 Gene Proliferation Score (6GPS) demonstrated independent prognostic value when adjusted for traditional clinicopathologic variables and the molecular subtypes. The 6GPS significantly associated also with disease-specific survival within the luminal, lymph node-negative and Oncotype Dx intermediate subset. CONCLUSIONS: We here demonstrate evidence of higher tumour cell proliferation in young BC patients, also when adjusting for molecular subtypes, and identified a novel age-based six-gene signature pointing to aggressive tumour features, tumour proliferation, and reduced survival-also in patient subsets with expected good prognosis.
BACKGROUND AND OBJECTIVE: Breast cancer (BC) diagnosed at ages <40 years presents with more aggressive tumour phenotypes and poorer clinical outcome compared to older BC patients. Here, we explored transcriptional BC alterations to gain a better understanding of age-related tumour biology, also subtype-stratified. METHODS: We studied publicly available global BC mRNA expression (n = 3999) and proteomics data (n = 113), exploring differentially expressed genes, enriched gene sets, and gene networks in the young compared to older patients. RESULTS: We identified transcriptional patterns reflecting increased proliferation and oncogenic signalling in BC of the young, also in subtype-stratified analyses. Six up-regulated hub genes built a novel age-related score, significantly associated with aggressive clinicopathologic features. A high 6 Gene Proliferation Score (6GPS) demonstrated independent prognostic value when adjusted for traditional clinicopathologic variables and the molecular subtypes. The 6GPS significantly associated also with disease-specific survival within the luminal, lymph node-negative and Oncotype Dx intermediate subset. CONCLUSIONS: We here demonstrate evidence of higher tumour cell proliferation in young BC patients, also when adjusting for molecular subtypes, and identified a novel age-based six-gene signature pointing to aggressive tumour features, tumour proliferation, and reduced survival-also in patient subsets with expected good prognosis.
Authors: Hatem A Azim; Stefan Michiels; Philippe L Bedard; Sandeep K Singhal; Carmen Criscitiello; Michail Ignatiadis; Benjamin Haibe-Kains; Martine J Piccart; Christos Sotiriou; Sherene Loi Journal: Clin Cancer Res Date: 2012-01-18 Impact factor: 12.531
Authors: T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale Journal: Proc Natl Acad Sci U S A Date: 2001-09-11 Impact factor: 11.205
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: Carey K Anders; David S Hsu; Gloria Broadwater; Chaitanya R Acharya; John A Foekens; Yi Zhang; Yixin Wang; P Kelly Marcom; Jeffrey R Marks; Phillip G Febbo; Joseph R Nevins; Anil Potti; Kimberly L Blackwell Journal: J Clin Oncol Date: 2008-07-10 Impact factor: 44.544
Authors: Ann H Partridge; Shari Gelber; Martine J Piccart-Gebhart; Florine Focant; Matthew Scullion; Eileen Holmes; Eric P Winer; Richard D Gelber Journal: J Clin Oncol Date: 2013-06-10 Impact factor: 44.544
Authors: Hanna Fredholm; Kristina Magnusson; Linda S Lindström; Hans Garmo; Sonja Eaker Fält; Henrik Lindman; Jonas Bergh; Lars Holmberg; Fredrik Pontén; Jan Frisell; Irma Fredriksson Journal: Breast Cancer Res Treat Date: 2016-09-13 Impact factor: 4.872